Kinnov-Therapeutics will be present at the 16th International Congress of Addictology of the Albatros in Paris on June 7, 8 and 9, 2022.
Two conferences will be given: one, presenting the “Cocktail” study, a randomized, placebo-controlled proof-of-concept phase 2 trial, testing the simultaneous blockade of α1b-adrenergic and 5HT2A-serotonergic receptors for the treatment of alcohol use disorder ; the other, presenting the positive results of the “Cocktail” study that strongly suggest that combined prazosin and cyproheptadine can be efficient as a therapy to treat alcoholism in Human.
Here are the abstract of these two conferences :
Kinnov-Therapeutics will be present at the 16th International Congress of Addictology